Take Two Shrooms and Call Me in the Morning: The Medical Promise of Magic Mushrooms

SIX YEARS AGO, on a late fall evening, I stood in front of a pinball machine, flummoxed. The game was space themed, with an elaborate UFO in the middle surrounded by a kaleidoscope of flashing lights. I was mesmerized, but I had no idea how to make it start. The machine’s coin slot and glowing buttons were suddenly indecipherable. Time felt like it had slowed to a crawl, and I became paranoid that the handful of people in the bar were staring at me, wondering what I was doing. It was then I realized that the magic mushrooms were kicking in.

This was the first time I’d taken a hallucinogen since my early twenties. Back then, as a university student, it was a lark. Now, in my forties with a family, the idea was daunting. This trip, however, had a medical purpose: for nearly two decades, I’ve struggled with a rare illness known as cluster headaches. Cluster headaches have been described as more painful than childbirth and kidney stones; they’re sometimes referred to as “suicide headaches” because of the mental toll they take. These headaches happen in groups—for me, they occur two or three times a day for weeks on end. Like migraines, they’re difficult to treat. Over the years, I’ve visited countless neurologists, chiropractors, acupuncturists, and naturopaths. I’ve taken prescriptions and experimented with cleanses and diets. Nothing worked.

Then I stumbled onto Clusterbusters, a popular message board created by a fellow sufferer, where people around the world could swap advice. There was one tip that was gaining traction: multiple posters were reporting that, after they had consumed magic mushrooms, their headaches had abruptly—miraculously—stopped. I was in the midst of a headache cycle at the time and was desperate to stop the pain. I reached out to a long-time friend in Toronto, and not long afterward, we downed a handful of dry, fishy-tasting fungi in his newly renovated kitchen.

Keep reading

Congress Should Let D.C. Decriminalize Psychedelics, Advocates Say

Drug policy reform advocates are asking a key congressional committee to reject a Republican lawmaker’s attempt to block Washington, D.C. from enacting an initiative to decriminalize certain psychedelics.

Rep. Andy Harris (R-MD)—who has also championed provisions preventing D.C. from implementing legal marijuana sales after local voters passed a cannabis initiative in 2014—signaled last week that he’s planning to introduce an amendment to a spending bill during a committee meeting on Wednesday that would restrict the District from allowing the psychedelics measure to be implemented even if it is approved by voters in November.

The Drug Policy Alliance (DPA) is in favor of the proposal and, on Tuesday, it sent a letter to leadership in the House Appropriations Committee asking members to oppose Harris’s amendment and any other effort to restrict the democratic process for D.C. residents.

The measure, which hasn’t formally qualified for the ballot yet but received significantly more signatures than required when activists submitted them last week, would make a wide range of entheogenic substances including psilocybin mushrooms and ayahuasca among the jurisdiction’s lowest law enforcement priorities. However, it wouldn’t technically change local statute.

Keep reading